How Self-Assembling Peptides Cross Cell Walls and Deliver Cancer Drugs Directly to Tumors

Comprehensive literature review of published research on self-assembling peptide nanomedicines in cancer therapy, covering transmembrane transport mechanisms, targeting peptide strategies, and current challenges in clinical translation.

Cancer drugs often damage healthy cells alongside tumors, causing severe side effects. Self-assembling peptides offer a potential solution: they can form nanostructures that encapsulate drugs, cross cell membranes efficiently, and deliver their cargo specifically to tumors. Understanding the different transmembrane mechanisms and targeting strategies is essential for designing the next generation of peptide-based cancer nanomedicines. This review provides a comprehensive roadmap for researchers working to translate SAP technologies from the lab to clinical use.

Peptide-based nanomedicine is one of the fastest-growing areas in drug delivery. Self-assembling peptides combine the advantages of biological molecules (biocompatibility, low immunogenicity) with the engineering possibilities of nanotechnology (controlled size, shape, and drug release). As cancer treatment moves toward precision medicine, the ability to combine self-assembly with tumor-specific targeting peptides could enable 'smart' drug delivery systems that attack tumors while leaving healthy tissue unharmed. Several SAP systems are approaching clinical trials, making this review timely for understanding the state of the art.

As a review, this paper summarizes existing research rather than presenting new experimental data. Most SAP nanomedicine systems discussed remain preclinical. The clinical translation challenges highlighted — including stability, manufacturing scalability, and regulatory pathways — are significant and largely unresolved. The review may not capture the most recent developments given the rapidly evolving field.